- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies - - The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreat
This is the newest page. Registered accounts read further back.